KBP Biosciences: Ocedurenone (KBP-5074) Featured at ASN Kidn

Hepatic Impairment and Drug-Drug Interaction Study Results Presented PRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ -- KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage

Related Keywords

United States , San Antonio , Texas , Michigan , American , Kostenloser Wertpapierhandel , James Mccabe , University Of Chicago Medical Center , American Heart Association Comprehensive Hypertension Center , American Heart Association Scientific Sessions , Renal Associates , University Of Michigan , Hepatic Impairment , Drug Interaction Study Results , Pablo Pergola , Mineralocorticoid Receptor Blocker , Uncontrolled Hypertension , American Heart Association , Comprehensive Hypertension Center , Chicago Medical Center , Drug Interaction , Moderate Hepatic , Deputy Chief Medical , Julia Yang , Chief Operations Officer , Bertram Pitt , Fred Yang Phd , Chief Development Officer , Moderate Hepatic Impairment , Healthy Subjects , Kidney Disease , Clinical Trial , Biosciences , Ocedurenone , 8074 , Featured , Kidney , Eek , Potential , Treatment , Option , Patients , Uncontrolled , Resistant , Hypertension , Dvanced ,